Inflammatory Bowel Disease Market Forecast to 2036: Market Insights and Trends
DelveInsight's new report analyzes the Inflammatory Bowel Disease (IBD) market through 2036. The market was valued at approximately USD 21 billion in 2025 and is projected for significant growth.
The global market for Inflammatory Bowel Disease (IBD) treatments is projected for significant growth through 2036, according to a new report by DelveInsight. The "Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2036" report indicates the market was valued at approximately USD 21 billion in 2025.
Key drivers for this expansion include increasing disease prevalence, the development of novel therapies, and evolving treatment strategies. The analysis covers major markets such as the United States, EU4 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan, providing stakeholders with insights into epidemiology, market dynamics, and therapeutic advancements.
Recent developments highlight the dynamic nature of the IBD landscape. In September 2026, Spyre Therapeutics reported positive Phase II results for its anti-IL-23 antibody SPY003 in ulcerative colitis. In August 2026, Stelara (ustekinumab) received FDA approval for pediatric patients with moderately to severely active ulcerative colitis, marking a significant step in treating young IBD patients.
Further advancements include the FDA approval of Immgolis, the first interchangeable biosimilars to golimumab, in May 2026. Eli Lilly and Company reported durable disease clearance with mirikizumab in ulcerative colitis patients over four years, while Johnson & Johnson's Phase III study for guselkumab in Crohn's disease met its primary endpoint. AbbVie is also advancing its application for risankizumab in Crohn's disease treatment.